HIV-hepatitis C virus co-infection in the era of direct-acting antivirals

Current HIV/AIDS Reports

Volumn 11, Issue 3, 2014, Pages 241-249

  Bichoupan, Kian ^a   Dieterich, Douglas T ^a   Martel Laferrière, Valérie ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Co infection; Hepatitis C virus (HCV); HIV; HIV AIDS; HIV HCV co infection; Sustained virologic response (SVR)

Indexed keywords

ANTIVIRUS AGENT; ASUNAPREVIR; BOCEPREVIR; DACLATASVIR; DASABUVIR; DIRECT ACTING ANTIVIRAL; FALDAPREVIR; GRAZOPREVIR; LEDIPASVIR; LEDIPASVIR PLUS SOFOSBUVIR; OMBITASVIR; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; UNCLASSIFIED DRUG;

CD4 LYMPHOCYTE COUNT; DRUG COST; GENOTYPE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS HEPATITIS C VIRUS COINFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LIVER CIRRHOSIS; MEDICAL HISTORY; MIXED INFECTION; PHYSICAL EXAMINATION; PREVALENCE; REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; COINFECTION; COMPLICATION; HEPACIVIRUS; VIROLOGY;

ANTIVIRAL AGENTS; COINFECTION; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HUMANS;

EID: 84925547894     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-014-0217-9     Document Type: Review

References (49)

1. Hernando V, Perez-Cachafeiro S, Lewden C, Gonzalez J, Segura F, Oteo JA, et al. All-cause and liver-related mortality in HIV positive subjects compared to the general population: differences by HCV coinfection. J Hepatol. 2012;57(4):743-51.
2. Qurishi N, Kreuzberg C, Luchters G, Effenberger W, Kupfer B, Sauerbruch T, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet. 2003;362(9397):1708-13. (Pubitemid 37468321)
3. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010;138(2):513-21. 21 e1-6.
4. Buti M, San Miguel R, Brosa M, Cabases JM, Medina M, Angel Casado M, et al. Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis C. J Hepatol. 2005;42(5):639-45.
5. Dieperink E, Pocha C, Thuras P, Knott A, Colton S, Ho SB. All-cause mortality and liver-related outcomes following successful antiviral treatment for chronic hepatitis C. Dig Dis Sci. 2014;59(4):872-80.
6. Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA.A sustained virologic response reduces risk of all-causemortality in patients with hepatitis C. Clin Gastroenterol Hepatol : Off Clin Pract J Am Gastroenterol Assoc. 2011;9(6):509-16.
7. van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA : J Am Med Assoc. 2012;308(24):2584-93.
8. Nunez M, Miralles C, Berdun MA, Losada E, Aguirrebengoa K, Ocampo A, et al. Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial. AIDS Res Hum Retrovir. 2007;23(8):972-82. (Pubitemid 47492337)
9. Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med. 2004;351(5):451-9. (Pubitemid 38988594)
10. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, Lazzarin A, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351(5):438-50. (Pubitemid 38988593)
11. Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA : J Am Med Assoc. 2004;292(23):2839-48. (Pubitemid 39628231)
12. Laguno M, Murillas J, Blanco JL, Martinez E, Miquel R, Sanchez-Tapias JM, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV coinfected patients. AIDS. 2004;18(13):F27-36. (Pubitemid 39179626)
13. Ioannou G, Scott JD, Yang Y, Green PK, Beste LA. Rates and predictors of response to anti-viral treatment for hepatitis C virus in HIV/HCV co-infection in a nationwide study of 619 patients. Aliment Pharmacol Ther. 2013;38(11-12):1373-84.
14. Urbanus AT, van de Laar TJ, Stolte IG, Schinkel J, Heijman T, Coutinho RA, et al. Hepatitis C virus infections among HIV-infected men who have sex with men: an expanding epidemic. AIDS. 2009;23(12):F1-7.
15. Boceprevir package insert. [cited 2013 December 30]; Available from:http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/202258lbl.pdf.
16. Pearlman BL. Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care. Lancet Infect Dis. 2012;12(9):717-28.
17. Sofosbuvir package insert. [cited 2013 December 30]; Available from:http://www.gilead.com/~/media/Files/pdfs/medicines/liverdisease/sovaldi/ sovaldi-pi.pdf.
18. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49(4):1335-74.
19. Bottieau E, Apers L, Van Esbroeck M, Vandenbruaene M, Florence E. Hepatitis C virus infection in HIV-infected men who have sex with men: sustained rising incidence in Antwerp, Belgium, 2001-2009. Euro surveillance : bulletin Europeen sur les maladies transmissibles =. Eur Commun Dis Bull. 2010;15(39):19673.
20. van der Helm JJ, Prins M, del Amo J, Bucher HC, Chene G, Dorrucci M, et al. The hepatitis C epidemic among HIV-positive MSM: incidence estimates from 1990 to 2007. AIDS. 2011;25(8):1083-91.
21. Centers for Disease C. Prevention. Sexual transmission of hepatitis C virus among HIV-infected men who have sex with men-New York City, 2005-2010. MMWR Morb Mortal Wkly Rep. 2011;60(28):945-50.
22. Rauch A, Rickenbach M,Weber R, Hirschel B, Tarr PE, Bucher HC, et al.Unsafe sex and increased incidence of hepatitis C virus infection among HIV-infected men who have sex with men: the Swiss HIV Cohort Study. Clin Infect Dis : Off Publ Infect Dis Soc Am. 2005;41(3):395-402. (Pubitemid 41022120)
23. Lambers FA, Prins M, Thomas X, Molenkamp R, Kwa D, Brinkman K, et al. Alarming incidence of hepatitis C virus re-infection after treatment of sexually acquired acute hepatitis C virus infection in HIV-infected MSM. AIDS. 2011;25(17):F21-7.
24. Martin TC, Martin NK, Hickman M, Vickerman P, Page EE, Everett R, et al. Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM. AIDS. 2013;27(16):2551-7.
25. Ingiliz P, Krznaric I, Stellbrink HJ, Knecht G, Lutz T, Noah C, et al. Multiple hepatitis C virus (HCV) reinfections in HIV-positive men who have sex with men: no influence of HCV genotype switch or interleukin-28B genotype on spontaneous clearance. HIV Med. 2014. doi:10.1111/hiv.12127.
26. Al-Mohri H, Murphy T, Lu Y, Lalonde RG, Klein MB. Evaluating liver fibrosis progression and the impact of antiretroviral therapy in HIVand hepatitis C coinfection using a noninvasive marker. J Acquir Immune Defic Syndr. 2007;44(4):463-9. (Pubitemid 46555383)
27. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43(6):1317-25. (Pubitemid 43980111)
28. Bruix J, Sherman M. Management of Hepatocellular Carcinoma: An Update. Available from: http://www.aasld.org/practiceguidelines/Documents/Bookmarked Practice Guidelines/HCCUpdate2010.pdf.
29. Garcia-Tsao G, Sanyal A, Grace N, Carey W. Prevention and Management of Gastroesophageal Varices and Variceal Hemorrhage in Cirrhosis. Available from: http://www.aasld.org/practiceguidelines/Documents/Bookmarked Practice Guidelines/Prevention and Management of Gastro Varices and Hemorrhage.pdf.
30. Martel-Laferriere V, Dieterich DT. Treating HCV in HIV 2013: on the cusp of change. Liver Int : Off J Int Assoc Study Liver. 2014;34 Suppl 1:53-9.
31. Opravil M, Sasadeusz J, Cooper DA, Rockstroh JK, Clumeck N, Clotet B, et al. Effect of baseline CD4 cell count on the efficacy and safety of peginterferon Alfa-2a (40KD) plus ribavirin in patients with HIV/hepatitis C virus coinfection. J Acquir Immune Defic Syndr. 2008;47(1):36-49. (Pubitemid 351619367)
32. Sulkowski MS, Sherman KE, Dieterich DT, Bsharat M, Mahnke L, Rockstroh JK, et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med. 2013;159(2):86-96.
33. Naggie S, Sulkowski M, Lalezari J, Fessel WJ, Mounzer K, Shuhart MC, et al. All-Oral Therapy With Sofosbuvir Plus Ribavirin For the Treatment of HCV Genotype 1, 2, 3 Infection in Patients Co-infected With HIV (PHOTON-1). 21th Conference on Retroviruses and Opportunistic Infections, Boston, USA. March 2014.
34. Martel-Laferriere V, Brinkley S, Bichoupan K, Posner S, Stivala A, Perumalswami P, et al. Virological response rates for telaprevir-based hepatitis C triple therapy in patients with and without HIV coinfection. HIV Med. 2013. doi:10.1111/hiv.12086.
35. Buti M, Agarwal K, Horsmans Y, Sievert W, Janczewska E, Zeuzem S, et al. Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C. Gastroenterology. 2014;146(3):744-53.e3.
36. Sulkowski MS, Sherman KE, Dieterich DT, Bsharat M, Mahnke L, Rockstroh JK, et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med. 2013;159(2):86-96.
37. Montes M, Nelson M, Girard P, Sasadeusz J, Horban A, Grinsztejn B, et al. Telaprevir Combination Therapy in Treatment-naive and - experienced Patients Co-infected with Hepatitis C Virus and HIV: Week 12 Analysis of INSIGHT. 64th Annual Meeting of the American Association of the Study of Liver Diseases; Washington, DC Nov 1-5 2013.
38. Cotte L, Vincent C, Sogni P, Fournier I, Aumaitre H, De Truchis P, et al. Telaprevir in Treatment-Experienced HIV-HCV G1 Coinfected Patients (ANRS HC26 TelapreVIH) 21st Conference on Retroviruses and Opportunistic Infections; Bosto, MA March 3-6, 20142014.
39. Neukam K, Munteanu D, Rivero A, Haberl A, Marquez M, Ingiliz P, et al. Boceprevir/Telaprevir-Based Therapy in HIV-Infection: Interim Analysis of a Multicenter Cohort 21st Conference on Retroviruses and Opportunistic Infections; Bosto, MA March 3-6, 20142014.
40. Gori A, Doroana M, Chernova O, Rockstroh J, Banhegyi D, Bergin C, et al. Telaprevir Treatment of HIV/HCV G1 Patients With Severe Fibrosis: Efficacy Results To Week 16. 21th Conference on Retroviruses and Opportunistic Infections, Boston, USA March 2014.
41. Cotte L, Barrail-Tran A, Vincent C, Valantin M, Fournier I, Lacombe K, et al. Telaprevir Increases Ribavirin Toxicity Through eGFR Decrease in HIV-HCV Coinfected Patients 21st Conference on Retroviruses and Opportunistic Infections; Bosto, MA March 3-6, 20142014.
42. Poizot-Martin I, Bellissant E, Colson P, Renault A, Piroth L, Solas C, et al. Boceprevir for Previously Treated HCV-HIV Coinfected Patients: The ANRS-HC27 BocepreVIH Trial 21th Conference on Retroviruses and Opportunistic Infections, Boston, USA March 2014.
43. Rodriguez-Torres M, Rodriguez-Orgengo J, Gaggar A, Shen G, Symonds B, McHutchison J, et al. Infectious Disease Week October 2-6, 2013; San Francisco.
44. Hagan LM, Sulkowski MS, Schinazi RF. Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals. Hepatology. 2014;60(1):37-45.
45. Jacobson I, Ghalib R, Rodriguez-Torres M, Younossi Z, Corregidor A, Sulkowski M, et al. SVR results of a oncedaily regimen of simeprevir (SMV, TMC435) plus sofosbuvir (SOF, GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naïve and prior null responder patients: The COSMOS study 64th Annual Meeting of the AMerican Association for th Study of Liver Diseases; Washington, DC Nov 1-5 2013
46. Lawitz E, Hezode C, Gane E, Tam E, Lagging M, Balart L, et al. Efficacy and safety of MK-5172 and MK-8742 ± RIBAVIRIN IN Hepatitis C Genotype 1 Infected Patients with cirrhosis or previous null response: the C-WORTHY Study. EASL - The International Liver Congress 2014 49th Annual Meeting of the European Association for the Sudy of the Liver; London, United Kingdom April 9-13.
47. Kowdley KV, Lawitz E, Poordad F, Cohen DE, Nelson DR, Zeuzem S, et al. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med. 2014;370(3):222-32.
48. Kohli A, Sims Z, Miriam M, Nelson A, Osinusi A, Bon D, et al. Combination Oral, Hepatitis C Antiviral Therapy for 6 or 12 Weeks: Results of the SYNERGY Trial 21st Conference on Retroviruses and Opportunistic Infections; Boston, MA March 3-6, 2014.
49. Hezode C, Bruno S, Jacobson I, Serfaty L, Kwo P, Zhou A, et al. Safety and Efficacy of MK-5172 Plus Peginterferon Alfa-2b and Ribavirin (PR) in Cirrhotic and Noncirrhotic Treatment-Naive Patients With Hepatitis C Virus (HCV) Genotype (G)1 Infection EASL - The International Liver Congress 2014 49th Annual Meeting of the European Association for the Study of the Liver; London, United Kingdom April 9-13.